Takeda Pharmaceutical Company, García-Sancho, Alejandro Martín, Rodríguez-Pinilla, Socorro María, Domingo-Domènech, Eva, Climent, Fina, Sanchez-Garcia, Joaquin, López Jiménez, Javier, García-Cosío, Mónica, Castellví, Josep, González, Ana Julia, González de Villambrosia, Sonia, Gómez Codina, José, Navarro, Belén, Rodríguez, Guillermo, Borrero, Juan J., Fraga, Máximo, Naves, Andrea, Baeza, Lourdes, Córdoba, Raúl, Takeda Pharmaceutical Company, García-Sancho, Alejandro Martín, Rodríguez-Pinilla, Socorro María, Domingo-Domènech, Eva, Climent, Fina, Sanchez-Garcia, Joaquin, López Jiménez, Javier, García-Cosío, Mónica, Castellví, Josep, González, Ana Julia, González de Villambrosia, Sonia, Gómez Codina, José, Navarro, Belén, Rodríguez, Guillermo, Borrero, Juan J., Fraga, Máximo, Naves, Andrea, Baeza, Lourdes, and Córdoba, Raúl
Nodal peripheral T-cell lymphoma (PTCL) with a T follicular helper phenotype (PTCL-TFH) is a new type of PTCL. We aimed to define its clinical characteristics and prognosis compared to PTCL not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL). This retrospective observational study included 175 patients diagnosed with PTCL between 2008 and 2013 in 13 Spanish sites. Patient diagnosis was centrally reviewed, and patients were reclassified according to the World Health Organization (WHO) 2016 criteria: 21 patients as PTCL-NOS, 55 as AITL and 23 as PTCL-TFH. Median follow-up was 56.07 months (95% CI 38.7–73.4). Progression-free survival (PFS) and overall survival (OS) were significantly higher in patients with PTCL-TFH than in those with PTCL-NOS and AITL (PFS, 24.6 months vs. 4.6 and 7.8 months, respectively, p = 0.002; OS, 52.6 months vs. 10.0 and 19.3 months, respectively, p < 0.001). Histological diagnosis maintained an independent influence on both PFS (hazard ratio [HR] 4.1 vs. PTCL-NOS, p = 0.008; HR 2.6 vs. AITL, p = 0.047) and OS (HR 5.7 vs. PTCL-NOS, p = 0.004; HR 2.6 vs. AITL, p = 0.096), regardless of the International Prognostic Index. These results suggest that PTCL-TFH could have more favourable features and prognosis than the other PTCL subtypes, although larger series are needed to corroborate these findings.